Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to provide testing and contract research support for the ADAPT precision cancer therapy program. Under the agreement Tempus will supply multiple genomic and AI‑based diagnostics—including whole transcriptome RNA‑seq, exome panels, liquid biopsy assays and its Compass CRO services—to projects focused on biomarker‑guided treatments for breast, colorectal and non‑small cell lung cancers. Tempus CEO Eric Lefkofsky said the company will integrate its data platforms and assays with ADAPT’s experimental trial designs. The contract gives ARPA‑H a private‑sector partner for large‑scale sequencing and analytic workloads tied to adaptive, biomarker‑driven therapeutic strategies. ADAPT has previously funded academic and private groups; Tempus’ award signals a push to operationalize AI and multiomic assays across the program. The work will include central testing and data integration to support trial readouts and downstream therapeutic decisions. The award highlights continued government investment in AI‑enabled precision oncology infrastructure and validates Tempus’ assay suite as an enterprise diagnostic vendor for complex, adaptive clinical research.